Interleukins allergic asthma

Wuyts A, Overbergh L, Mathieu C, Ceuppens JL Interleukin-17 orchestrates the granulocyte influx into airways after allergen inhalation in a mouse model of allergic asthma. Am J Respir Cell Mol Biol 2003 28 42-50. 

Wills-Karp M, Luyiambazi J, Xu X, Schofield B, et al. 1998. Interleukin-13 Central mediator of allergic asthma. Science. 282 2258-2261. 

B. Schofield, T.Y. Neben, C.L. Karp, D.D. Donaldson, Interleukin-13 central mediator of allergic asthma, Science 1998, 282, 2258. 

Zhu Z, Homer RJ, Wang Z, et al Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production J Clin Invest 1999, 103 779-788 WiUs-JCarp M, Luyimbazi J, Xu X, et al Interleukin-13 central mediator of allergic asthma [see comments] Science 1998, 282 2258-2261... 

Warringa, R. A., Mengelers, H. J., Raaijmakers, J. A., Bruijnzeel, P. L., and Koenderman, L. (1993) Upregulation of formyl-peptide and interleukine-8-induced eosinophil chemotaxis in patients with allergic asthma. J. Allergy Clin. Immunol. 91,1198-1205. 

Ohashi Y, Nakai Y, Tanaka A, Kakinoki Y, Ohno Y, Masamoto T, Sakamoto H, Kato A, Washio Y, Hayashi M Serum levels of specific IgE, soluble interleukin-2 receptor, and soluble intercellular adhesion molecule-1 in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997 79 213-220. 

Ohashi Y, Nakai Y, Sakamoto H, Ohno Y, Sugiura Y, Okamoto H, Tanaka A, Kakinoki Y, Kishimoto K, Hayashi M Serum levels of soluble interleukin-2 receptor in patients with perennial allergic rhinitis before and after immunotherapy. Ann Allergy Asthma Immunol 1996 77 203-208. Ohashi Y, Nakai Y, Tanaka A, Kakinoki Y, Washio Y, Kato A, Masamoto T, Sakamoto H, Yamada K Ten-year follow-up study of allergen-specific immunoglobulin E and immunoglobulin G4, soluble interleukin-2 receptor, interleukin-4, soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1 in serum of patients on immunotherapy for perennial allergic rhinitis. Scand J Immunol 1998 47 167-178. 

Nishikubo, K., Murata, Y., Tamaki, S., Sugama, K., Imanaka-Yoshida, K., Yuda, N., Kai, M., Takamura, S., Sebald, W., Adachi, Y. and Yasutomi, Y. (2003). A single administration of interleukin-4 antagonistic mutant DNA inhibits allergic airway inflammation in a mouse model of asthma. GeneTher. 10, 2119-2125. 

In another study a group of adults was immunised with the live measles vaccine, this resulted in activation of Th2 cells producing interleukin-4 [ 170(IIa)]. In a small retrospective cohort study in Christchurch, New Zealand, involving school-aged children, there were lower rates of asthma or allergic disease among the 1.8% of uii-immuiiised children [171 (IIIC)]. 

Schleimer RP, Sterbinsky SA, Kaiser J, Bickel CA, Klunk DA, Tomioka K, Newman W, Luscinskas FW, Gimbrone MA Jr, McIntyre BW, et al. Interleukin-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium association with expression of VCAM-1. J Immunol 1992 148 1086-1092. Montefort S, Holgate ST, Howarth PH. Leucocyte-endothelial adhesion molecules and their role in bronchial asthma and allergic rhinitis. Eur Respir J 1993 6 1044-1054. 

---